id,agency_id,docket_id,title,document_type,subtype,posted_date,posted_year,posted_month,comment_start_date,comment_end_date,last_modified,fr_doc_num,open_for_comment,withdrawn,object_id
FDA-2011-P-0086-0011,FDA,FDA-2011-P-0086,Agency Response Letter to Risperidone Staleness,Other,Agency Response,2022-06-17T04:00:00Z,2022,6,2022-06-17T04:00:00Z,,2022-06-17T15:29:57Z,,0,0,09000064851793a1
FDA-2011-P-0086-0012,FDA,FDA-2011-P-0086,Agency Response Letter to Risperidone,Other,Agency Response,2022-06-17T04:00:00Z,2022,6,2022-06-17T04:00:00Z,,2022-06-17T15:31:43Z,,0,0,09000064851793a3